Intrinsiqs

Is Regeneron Pharmaceuticals, Inc. overvalued?

Regeneron Pharmaceuticals, Inc. (REGN) looks overvalued — trading about 19% above its fair value.

Overvalued
Current price $955.47 Fair value $773.52
Price
$955.47
Fair value
$773.52
Current P/E
23.0
Normal P/E
18.6
Market cap
$98.82B
Dividend yield
0.4%
Return on equity
15.1%
Sector
Healthcare

See the full interactive analysis →

Fair value compares REGN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 15 Nov 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.RHHBY Roche Holding AGUNH UnitedHealth Group IncorporatedMRK Merck & Co., Inc.